P&PAULSON & CO. INC.
Institutional investor · Portfolio as of Q3 2019
Top Holdings45 positions
SPDR GOLD TRUST GOLD SHS | 4.3M | $599.9M | 12.0% | $141.06 | 0.00% | 1 qtr | First report 0 |
Allergan PLC | 2.9M | $493.5M | 9.9% | — | — | 1 qtr | First report 0 |
Valeant Pharmaceuticals Intern | 20.8M | $455.3M | 9.1% | $21.70 | 0.00% | 1 qtr | First report 0 |
Celgene Corp | 3.2M | $317.2M | 6.4% | — | — | 1 qtr | First report 0 |
Discovery Communications Inc | 10.9M | $268.9M | 5.4% | — | — | 1 qtr | First report 0 |
Mylan NV | 12M | $237.5M | 4.8% | — | — | 1 qtr | First report 0 |
| 12.8M | $233.5M | 4.7% | $4.23 | 0.00% | 1 qtr | First report 0 | |
TAKEDA PHARMACEUTICAL CO-SPON ADR | 13.2M | $227.8M | 4.6% | $16.10 | 0.00% | 1 qtr | First report 0 |
Horizon Pharma Plc | 8.2M | $222.5M | 4.5% | — | — | 1 qtr | First report 0 |
BRIGHTSPHERE INVT GROUP INC | 20M | $198.2M | 4.0% | $9.52 | 0.00% | 1 qtr | First report 0 |
DISH Network Corp | 5M | $169.4M | 3.4% | — | — | 1 qtr | First report 0 |
Yahoo! Inc | 7.6M | $148.2M | 3.0% | — | — | 1 qtr | First report 0 |
WellCare Health Plans Inc | 561,397 | $145.5M | 2.9% | — | — | 1 qtr | First report 0 |
SPARK THERAPEUTICS INC | 1.4M | $139.4M | 2.8% | — | — | 1 qtr | First report 0 |
Novagold Resources Inc | 22M | $133.5M | 2.7% | $6.33 | 0.00% | 1 qtr | First report 0 |
Tesla Inc | 500,000 | $120.4M | 2.4% | — | — | — | First report — |
SOTHEBYS | 1.9M | $105.6M | 2.1% | — | — | 1 qtr | First report 0 |
CALLON PETE CO DEL | 21.6M | $93.7M | 1.9% | — | — | 1 qtr | First report 0 |
| 12.6M | $77.7M | 1.6% | — | — | 1 qtr | First report 0 | |
PACIRA BIOSCIENCES INC | 1.7M | $65.4M | 1.3% | $40.00 | 0.00% | 1 qtr | First report 0 |
PAULSON & CO. INC. manages $5B across 45 positions as of Q3 2019. Top holdings: GLD (12.0%), AGN (9.9%), BHC (9.1%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 3/5.0.
First quarter we have for this fund: 45 positions, nothing earlier to compare. No standout high-conviction moves this quarter. Portfolio: $5.0B across 45 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR